Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Vomiting 31Nausea 24Neoplasms 8Lymphoma 8Breast Neoplasms 8Multiple Myeloma 6Leukemia, Myeloid, Acute 6Ovarian Neoplasms 5Lymphoma, Non-Hodgkin 5Sezary Syndrome 4Myeloproliferative Disorders 4Leukemia 4Carcinoma, Non-Small-Cell Lung 4Pruritus 3Primary Myelofibrosis 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pdgfra-Associated Chronic Eosinophilic Leukemia 3Neoplasms, Plasma Cell 3Myelodysplastic Syndromes 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Neutrophilic, Chronic 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Leukemia, Lymphocytic, Chronic, B-Cell 3

Interventions

Temozolomide 109Magnetic Resonance Spectroscopy 52Bevacizumab 52Radiotherapy 44Irinotecan 27Blood Specimen Collection 19Surgical Procedures, Operative 16Radiation 15Aminolevulinic Acid 15Carboplatin 13fluorodopa F 18 12Nivolumab 12Radiotherapy, Intensity-Modulated 11Carmustine 11Radiosurgery 10Magnetic Resonance Imaging 10pembrolizumab 9Topotecan 9Specimen Handling 9Everolimus 9Erlotinib Hydrochloride 9Biopsy 9poly ICLC 8Surveys and Questionnaires 8Standard of Care 8Etoposide 8Drug Therapy 8Lomustine 7Filgrastim 7Cyclophosphamide 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Glioma × Aprepitant × Clear all
NCT01450826 2018-06-26

Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide

Duke University

Phase 2 Completed
136 enrolled 10 charts
CNS

Glioma, Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡